

## HEIDELBERG

# HEALTH ECONOMICS SUMMER SCHOOL

HEIDELBERG, STUDIO VILLA BOSCH, JULY 01 – JULY 05, 2019

The **German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ)**, the Hochschule Heilbronn and the University of Heidelberg are delighted to invite you to the Heidelberg Health Economics Summer School 2019.

The Summer School will introduce basic concepts of health economics and address practical issues faced by scholars involved in conducting, reporting, or interpreting results of economic evaluations. This will include a review of the challenges faced by health care policy makers responsible for allocating scarce resources or involved in health technology assessments (HTAs), reimbursement, or pricing decisions.

Health economists use specific tools, such as cost-effectiveness analysis (CEA), to inform decision makers. Conventionally, CEA is designed to help achieving the maximum potential health benefits given a resource constraint or "scarcity". Results of conventional CEAs may, however, contradict prevailing social norms and preferences. The Summer School will address the underlying issues by first introducing and reviewing the basic concepts and methods, followed by a modeling workshop. It will conclude with two days of an in-depth review of the strengths and limitations of the conventional approaches and their alternatives, where the participants and speakers will be able to discuss implications, potential solutions, and ways forward.

The Summer School will be comprised of three consecutive modules that will offer a comprehensive overview of principles and methods, which build upon one another but may also be booked separately.

Members of the experienced level international **Presenting Faculty** will include

- Prof. **Silvio Garattini** (IRCCS – *Istituto di Ricerche Farmacologiche Mario Negri*. Milan, Italy)
- Prof. **Sören Holm** (University of Manchester, UK, & University of Oslo, Norway)
- Prof. **Peter Kolominsky-Rabas** (University of Erlangen, Germany)
- Prof. **Maarten Postma** (University of Groningen, The Netherlands)
- Prof. **Gérard de Pourville** (ESSEC *École Supérieure des Sciences Économiques et Commerciale*. Paris, France)
- Prof. **Jeffrey Richardson** (Centre for Health Economics, Monash University. Melbourne, Australia)
- Prof. **Wendelin Schramm** (University of Applied Sciences Heilbronn, Germany)
- Prof. **Michael Schlander** (DKFZ & University of Heidelberg, Germany)

## PROGRAM OVERVIEW

### Module A - [Introductory Level]

- International Health Care Systems: Organization, Financing, Performance
- Fundamentals of Health Economics: Economics as a Way of Thinking
- Exercise: “The Ethics of Allocating Scarce Resources”
- Value and Valuation in Health Economics
- Exercise: “Health State Utility Measurement in Practice”
- Costing in Theory & Practice
- Exercise: “Cost Analysis” – Analyzing a Costing Study
- Cost Effectiveness Analysis in Practice
- Case Study: “Analyzing the Cost Effectiveness of a Cancer Screening Program”
- Economic Evaluation and HTA

### Module B - [Intermediate Level]

- Theoretical Foundations of Models
- Markov Methodology  
Implementing a three state model structure, building transition matrixes based on fixed probabilities (Markov chain), implementing a half-cycle correction, including cost; discounting and willingness-to-pay thresholds, including quality-of-life factors for calculating QALYs, implementing a second comparator to the model, how to expand from Markov chains to Markov processes (i.e. age and gender dependent mortality)
- Reporting the Results of a Health Economic Model

### Module C - [Intermediate / Advanced Level]

- Loopholes of the Conventional Logic of Cost Effectiveness
- Individual and Social Preferences: Empirical Evidence
- The Search for Solutions:
  - (1) Multi-Criteria Decision Analysis
  - (2) U.S. “Value Frameworks”
  - (3) Extended Cost per QALY Analysis
  - (4) Social Cost Value Analysis
- Case Studies:
  - (1) Precision Medicine and the “Value of a Cure”
  - (2) Expensive Drugs for Rare Diseases: Orphan Medicinal Products (OMPs)
  - (3) Highly Effective Drugs for Common Diseases: The Case of Hepatitis C Treatment
  - (4) Prevention versus Cure
- Stakeholder Perspectives:
  - (1) Academic Health Economists
  - (2) Providers
  - (3) Payers & Policy Makers

Conference website: <https://indico.dkfz.de/event/81/>;

Contacts: Dr. Karla Hernandez-Villafuerte, [k.hernandezvillafuerte@dkfz.de](mailto:k.hernandezvillafuerte@dkfz.de), ☎ +49 6221 42-1913,  
and Ramon Schaefer, [ramon.schaefer@dkfz.de](mailto:ramon.schaefer@dkfz.de), ☎ +49 6221 42-1914.